-
ALSO READ
Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets
Strides Pharma gains after getting USFDA approval
Zydus Cadila receives USFDA tentative approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets
Benchmarks extend losses; breadth turns weak
S&P, Nasdaq close higher
-
The drug maker on Thursday announced that it has received tentative approval from the US drug regulator for emtricitabine and tenofovir disoproxil fumarate tablets.
The drug maker has received tentative approval from the U.S. Food and Drug Administration (USFDA) to market emtricitabine and tenofovir disoproxil fumarate tablets 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg (US RLD: TRUVADA tablets).Emtricitabine and tenofovir disoproxil fumarate tablets are used with other HIV medications to help control HIV infection. This product is a combination of two different drugs: emtricitabine and tenofovir disoproxil fumarate and helps to decrease the amount of HIV in the body so that the immune system can work better.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 312 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of Cadila Healthcare was down 2.4% to Rs 422.15 on BSE. Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Cadila Healthcare reported 40.6% rise in consolidated net profit to Rs 512.50 crore on a 6.2% rise in net sales to Rs 3,753.70 crore in Q3 FY21 over Q3 FY20.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU